FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcomaDavid Milewski, Tanya V. Kalin, Sushmitha Vallabh et al.|Oncogene|2021Cited by 29
Prospective Molecular Characterization of Multiple Myeloma Patient Samples Identifies High-Risk Patients and Informs Treatment Sequences through Resistance Mechanisms to ImmunotherapiesPhillip Pham, Brian A. Walker, Parvathi Sudha et al.|Blood|2023Cited by 5
Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selectionParvathi Sudha, Brian A. Walker, Phillip Pham et al.|Blood Advances|2025Cited by 0